Document is current
Any future updates will be listed below
-
Authors
Fonseca, Cândida https://orcid.org/0000-0003-3019-5956
Garagarza, Cristina
Silva, Gil
Caires, Graça
Marques, Irene
Lopes, José António
Branco, Patrícia
Alves, Rui
Ferreira, Aníbal
- License Information
-
More Information
Article History
Accepted: 21 October 2024
First Online: 27 November 2024
Declarations
:
: Not applicable.
: All the authors have read and approved the final version of the manuscript and gave their consent for publication.
: C.F received consultancy fees, lectures, or sponsorship of scientific meetings from AstraZeneca, Bayer, Bial, Boehringer Ingelheim, Novartis, Novo Nordisk, Pfizer, Roche Diagnosis, Servier, CSL Vifor, companies that research and commercialize drugs for the treatment of heart failure patients. G.C. received speaking fees from Servier, Novartis, CSL Vifor, and Boehringer. C.G. is employed by Fresenius Medical Care as Head of the Nutrition Department. G.S. received speaking fees from CSL Vifor, AstraZeneca, Alnylam and Baxter. I.M. received speaking fees from AstraZeneca, Bayer, Bial, CSL Vifor, Daiichi-Sankyo, Novartis, Pfizer, Roche Diagnostics, and Servier. I.M. served on advisory boards for AstraZeneca, Bayer, Bial, CSL Vifor, Novartis, Novo Nordisk, and Servier. A.F. received Advisory Board and consultancy fees, lectures, or sponsorship of scientific meetings from AstraZeneca, Astellas, CSL Vifor, Fresenius Medical Care, MSD-Merck Sharp & Dohme companies.
